Epigenetic Markers in Perinatal Depression and Future Therapy

DOI

10.2991/assehr.k.211020.207How to use a DOI?

Keywords

Epigenetics, perinatal depression, depression, pregnancy woman

Abstract

An increasing trend of perinatal depression was seen over the last decade and in both developed and underdeveloped regions. The purpose of this paper is to summarize the most predominant predictor of depressive symptoms during the vulnerable periods before and after pregnancy. For example, numerous epidemiological and case-control studies demonstrated that family and society play crucial roles in influencing mothers’ mental states. More importantly, early life adversity such as childhood abuse, was indicated to increase the risk of depression by epigenetic embedding of inflammatory pathways. This biobehavioral process makes women more vulnerable during pregnancy and after giving birth. Antidepressant is an effective drug which was widely used to treat depression. Nevertheless, its exposure to infants during both prenatal and breastfeeding period is controlled for offspring’s development. Therefore, psychological interventions such as IPT and CBT are more efficient and acceptable to reduce depressive symptoms for most pregnant women. Because PD is a multifactorial disorder, more studies are needed to enhance targeted interventions that can reduce the impact of PD on maternal–infant health.

Copyright

© 2021, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Jinghan Ruan
PY  - 2021
DA  - 2021/10/21
TI  - Epigenetic Markers in Perinatal Depression and Future Therapy
BT  - Proceedings of the 2021 International Conference on Public Relations and Social Sciences (ICPRSS 2021)
PB  - Atlantis Press
SP  - 506
EP  - 511
SN  - 2352-5398
UR  - https://doi.org/10.2991/assehr.k.211020.207
DO  - 10.2991/assehr.k.211020.207
ID  - Ruan2021
ER  -